First Solar Inc. (FSLR) Financials Nov 20, 2014, 7:53
First Solar Inc. (FSLR) Financials Nov 20, 2014, 7:53 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for First Solar Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 2.09B 2.54B 2.75B 3.38B 3.29B
Cost of Goods Sold (COGS) incl. D&A 1.02B 1.37B 1.79B 2.52B 2.44B
COGS excluding D&A 893.83M 1.22B 1.56B 2.25B 2.2B
Depreciation & Amortization Expense 129.63M 156.09M 235.23M 265.4M 238.8M
Depreciation 124.6M 150.5M 230.2M 263.3M 237.9M
Amortization of Intangibles 5.03M 5.59M 5.03M 2.1M 900,000
Gross Income 1.06B 1.16B 959.32M 860.82M 848.08M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 359.47M 428.74M 586.68M 421.21M 407.33M
Research & Development 78.16M 94.8M 140.52M 132.46M 134.3M
Other SG&A 281.31M 333.95M 446.16M 288.75M 273.03M
Other Operating Expense 0 0 0 0 0
Unusual Expense 16.45M (18,000) 457.41M 464.63M 79.27M
EBIT after Unusual Expense (16.45M) 18,000 (457.41M) (464.63M) (79.27M)
Non Operating Income/Expense (10.09M) 13.7M 17.77M (10.6M) 627,000
Non-Operating Interest Income 9.74M 14.38M 13.39M 12.82M 16.75M
Equity in Affiliates (Pretax) - - - - 0
Interest Expense 2.27M 6,000 100,000 17.01M 639,000
Gross Interest Expense 8.91M 10.07M 15.35M 27.31M 10.46M
Interest Capitalized 6.64M 10.06M 15.25M 10.3M 9.82M
Pretax Income 686.31M 762.08M (53.71M) (39.8M) 378.22M
Income Tax 46.18M 97.88M (14.22M) 56.53M 25.18M
Income Tax - Current Domestic 21M 93.42M 118.24M 36.8M 45.27M
Income Tax - Current Foreign 60.21M 62.49M 23.05M 6.8M 788,000
Income Tax - Deferred Domestic (40.03M) (61.25M) (148.28M) 4.41M (9.79M)
Income Tax - Deferred Foreign 5M 3.21M (7.22M) 8.53M (11.09M)
Income Tax Credits - - - - 0
Equity in Affiliates - - - - 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 640.14M 664.2M (39.49M) (96.34M) 353.04M
Minority Interest Expense 0 0 0 0 0
Net Income 640.14M 664.2M (39.49M) (96.34M) 353.04M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 640.14M 664.2M (39.49M) (96.34M) 353.04M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 640.14M 664.2M (39.49M) (96.34M) 353.04M
EPS (Basic) 7.67 7.82 (0.46) (1.11) 3.77
Basic Shares Outstanding 83.5M 84.89M 86.07M 86.86M 93.7M
EPS (Diluted) 7.53 7.68 (0.46) (1.11) 3.70
Diluted Shares Outstanding 85.04M 86.49M 86.07M 86.86M 95.47M
EBITDA 835.02M 890.09M 607.87M 705.01M 679.55M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Papa John's in Hot Water Again? Look, just when you think the pizza game is all dough and cheesy goodness, along comes a legal scuffle to toss our assumptions. Bronstein, Gewirtz & Grossman, LLC has slapped a class action lawsuit against Papa John's International, Inc. (NASDAQ: PZZA), claiming the company and some of its higher-ups haven't been playing fair with the...
Continue Reading
Weather's Wrath and the Michigan Roof Here's the deal: Michigan doesn't mess around when it comes to weather. We're talking harsh winters with piles of snow, followed by muggy summers that toss storms like they're confetti. Keeping that roof in top shape isn't just some luxury; it’s a downright necessity. Gut-punch reality? Many ignore it until it's too late. That's...
Continue Reading
Rewriting the Playbook in Global Skincare AXIS-Y decided to do things their way, not just because they could afford to, but because they believed in their vision. Their strategy defies the trends-driven tactics of this cutthroat beauty world. Instead, they’ve been all about climate-inspired products and vegan, cruelty-free standards. And now, after notching up some...
Continue Reading
Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...
Continue Reading
Buying Coastal Property: A Balancing Act Ah, the dream of owning a piece of the beach in sunny South Florida. It sounds glamorous—something to brag about at the next family gathering. But let me tell you, diving into coastal property ownership isn't just about sipping cocktails by the ocean. It's about handling a fair share of headaches most folks don't anticipate....
Continue Reading
NeuralTrust's Strategic London Expansion In a world where AI agents are sprinting ahead of our security instincts, NeuralTrust makes a big play in the UK market, locking in their position with a new London office. This move isn't just about expansion—it's about tackling the tide of challenges head-on that comes with putting AI agents into the wild. London: A Hub for...
Continue Reading
Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...
Continue Reading
Stem Cells: The Next Frontier or Hype? Folks, stem cells are no longer just a sci-fi concept tucked away in lab coats. This sector's set to boom from USD 18.9 billion in 2026 to a whopping USD 32.57 billion by 2031. Yeah, you heard it right, a solid 11.5% compound annual growth rate. Now, whether you're an investor or just keeping your finger on the biotech pulse, there's...
Continue Reading
A European Partnership for Modern Connectivity Big players in the telecom industry are joining forces, and it's like watching a seasoned boxer find his perfect sparring partner. Today, Ekinops, a heavyweight in European connectivity, is shaking hands with 1&1 Versatel, a lead puncher in Germany's B2B communications. They're rolling out a unified connectivity portfolio...
Continue Reading
Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...
Continue Reading
Top 5 Most Recently Viewed Articles
Avocados From Mexico Achieves Prestigious Great Place To Work Certification Avocados From Mexico is widely recognized not just as the top-selling avocado brand in the United States, but also as a Certified Great Place To Work. This esteemed certification reflects the positive feedback from current employees regarding their experiences within the company. An impressive 97%...
Continue Reading
Etex's Strong Half-Year Financial Performance Etex has demonstrated significant resilience in its half-year financial performance, navigating a construction environment that remains largely unpredictable. This strength is highlighted by a steady sales volume and healthy margins, confirming the company's expectations for the period. Overview of Financial Results The...
Continue Reading
First Horizon Bank Officially Partners with NC Courage In an exciting development for women's sports, First Horizon Bank (NYSE: FHN) has been named the Official Bank of the North Carolina Courage, marking the start of a multiyear partnership aimed at bolstering community initiatives. This collaboration is an incredible opportunity to enhance support for women's athletics...
Continue Reading
Curis Prepares for Major Presentations at SNO Meeting LEXINGTON, Mass. — Curis, Inc. (NASDAQ: CRIS) is excited to share that the company will participate in the prestigious 30th Annual Meeting of the Society for Neuro-Oncology (SNO). This event is taking place soon, and Curis intends to showcase significant clinical data regarding emavusertib (CA-4948), a promising...
Continue Reading
Recent Advancements in PTSD Research Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck LLC have made headlines with the publication of a Phase 3 trial of brexpiprazole combined with sertraline for treating Post-Traumatic Stress Disorder (PTSD) in adults. The findings, appearing in JAMA Psychiatry, indicate a significant improvement in PTSD symptoms...
Continue Reading